Cingulate Inc Presents SMART Launch Approach at Indegene Digital Summit

KANSAS CITY, Kan., Sept. 17, 2026 /CourierPR/ -- Cingulate Inc, a biopharmaceutical company developing next-generation products using its proprietary Precision Timed Release (PTR) drug delivery platform, is set to present its approach to commercialization at the upcoming Indegene Digital Summit. The company’s Chairman and CEO, Shane J.

Schaffer’s presentation will explore how emerging pharmaceutical companies can retain ownership and strategic control of their assets while accessing the necessary capabilities, expertise, technology, and scale for successful commercialization. The discussion will cover alternatives to traditional commercialization models, such as building a large internal infrastructure, licensing to a larger pharmaceutical company, or divesting the asset entirely. Key topics will include the economics of pharmaceutical launches, partner ecosystem strategies, maintaining quality and accountability across a distributed model, and reducing commercialization risk while preserving strategic control.

“For emerging biopharma companies, there is an opportunity to rethink that model and build commercialization strategies around the individual asset. By combining a focused internal commercial core with the capabilities and scale of experienced external partners, companies can retain greater strategic control while pursuing a more capital-efficient approach to launch.”

Cingulate’s Chief Commercial Officer, Bryan Downey, will also participate in the summit. He will present in a session titled “Small & Mid-Size Pharma. Big-Time Launches: Reinventing the Launch Playbook.” The panel will address how small and mid-size pharmaceutical companies can build efficient, scalable commercialization organizations with fewer resources and a more focused portfolio. Downey will emphasize the importance of identifying the capabilities that need to be built internally, leveraging technology and strategic partners where they can add value, and establishing the necessary infrastructure well before approval.

Cingulate is currently focused on the development of CTx-1301, a once-daily, multi-core tablet utilizing its PTR platform to deliver three precisely timed releases of active medication across the day. This design aims to provide rapid onset of effect and an entire active-day duration. CTx-1301 is being evaluated for the treatment of attention-deficit/hyperactivity disorder (ADHD) under the FDA’s 505(b)(2) pathway. In October 2025, the FDA accepted the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026. On June 1, 2026, the FDA issued a Complete Response Letter for the CTx-1301 NDA, and the company is working to complete the requested CMC work and plans to resubmit the NDA as promptly as practicable.

The Precision Timed Release (PTR) platform technology is designed to achieve true once-daily dosing for a range of conditions, including ADHD and anxiety disorders. Cingulate aims to use this technology to develop additional product candidates in other therapeutic areas, expanding its clinical-stage pipeline.

Cingulate Inc, headquartered in Kansas City, is focused on improving the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company is leveraging its PTR technology to develop next-generation pharmaceutical products and is actively working to advance its pipeline of clinical-stage product candidates.